Open AccessAngiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
Author(s) -
Berkay Ekici,
Mehmet Yaman,
Murathan Küçük,
Seçkin Dereli,
Mustafa Yenerçağ,
Zerrin Yiğit,
Memduh Baş,
Yusuf Karaveli̇oğlu,
Hüseyin Altuğ Çakmak,
Tarık Kıvrak,
Hakan Özkan,
Cihan Altın,
Cengiz Şabanoğlu,
Burcu Demirkan,
Ali Ataş,
Fethi Kılıçaslan,
Hakan Altay,
İstemihan Tengiz,
Aycan Fahri Erkan,
Barış Kılıçaslan,
Fatih Erkam Olgun,
Murtaza Emre Durakoğlugil,
Aslıhan Alhan,
Mehdi Zoghi
Publication year - 2021
Publication title -
türk kardiyoloji derneği arşivi
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.2
H-Index - 24
ISSN - 1016-5169
DOI - 10.5543/tkda.2021.63099
Subject(s) - ejection fraction , sacubitril , heart failure , medicine , valsartan , cardiology , ventricle , natriuretic peptide , diuretic , ace inhibitor , blood pressure , angiotensin converting enzyme
Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey.